A trial that enrolls adults from eighteen upward reports an average, and an average is not a finding about a 74-year-old. Age changes three things at once in this drug class: what the treatment is being asked to accomplish, what tissue leaves with the fat, and how many other prescriptions a weekly injection has to coexist with. The evidence behind each of those is a different size, which matters before reading the cardiovascular results as though they landed evenly across a lifespan.
The age floors let older adults in without studying them
SELECT is the outlier in the program. It enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index of 27 or greater without diabetes, and it randomized 17,604 of them.[1] A floor of 45 is not the same as a question about age, but it does mean the cohort skews far older than the weight-loss trials that produced the famous percentages.
The narrower question — what happens in people over 65 — has its own literature, and that literature is small. A 2026 systematic review searched for randomized and observational studies of GLP-1 receptor agonists in adults aged 65 and over with obesity, with or without type 2 diabetes. It found five studies covering 1,229 participants.[2] That is the age-specific base in full.
Where subgroups were reported, the effect held
The most detailed age analysis pooled two cardiovascular outcome trials in type 2 diabetes and split them into four bands: 60 and under, over 60 to 65, over 65 to 70, and over 70. Semaglutide reduced major adverse cardiovascular events against placebo across every band, with most hazard ratios below 1.0 and no significant interaction by age.[3]
Weight reduction behaved the same way, consistent across the bands (p for interaction = 0.124). One thing did vary: the treatment difference in HbA1c was larger in the youngest band (p for interaction = 0.01).[3] The 2026 review of older adults reached a matching conclusion on its own terms, reporting weight and metabolic control comparable to younger people.[2]
What differed was the side-effect mix
That same review found no significant difference in serious adverse events between older and younger participants, with a pooled log odds ratio of 0.06 (p = 0.9). Older adults showed a trend toward less nausea (LOR −0.44, p = 0.06), but higher rates of constipation (LOR 0.72, p = 0.02) and of hypoglycemia (LOR 0.97, p < 0.001).[2]
Those two are worth separating from the general tolerability picture in what the trials recorded. A hypoglycemic episode is a different event at 78 than at 38, because the downstream risk is a fall rather than an unpleasant hour. Which medications in a regimen make that more likely is a question for the prescriber who holds the whole list.
Lean mass: a real concern with no age-specific answer
A 2026 narrative review gathered 21 studies estimating skeletal muscle mass, strength, composition or performance during treatment. Most found muscle loss accounting for 8.5% to 24.5% of total weight lost. Studies of muscle quality mostly reported improvement, through higher density and less fat infiltration, and studies of strength generally found no significant change.[4]
Then the limit. Only four of those 21 studies examined older adults specifically, and those four were methodologically heterogeneous enough that the review declined to compare them. Its stated conclusion is that the published literature is insufficient to determine whether older adults are more vulnerable to muscle loss on these drugs.[4]The pooled body-composition figures for adults generally are in the muscle article.
Fractures point two ways in the same study
A 2026 target trial emulation followed adults aged 50 to 90 with type 2 diabetes who newly started either a GLP-1 receptor agonist or a DPP-4 inhibitor. After matching, 133,606 patients were analyzed. Starting a GLP-1 was associated with lower three-year fragility fracture risk: hazard ratio 0.79 (95% CI, 0.76 to 0.83), with a number needed to treat of 126. Vertebral and hip or femur fractures showed the largest reductions.[5]
The stratified analysis is the half that travels. Among patients with type 2 diabetes the reduction held, at HR 0.91 (95% CI, 0.88 to 0.95). Among those without diabetes the association reversed, at HR 1.13 (95% CI, 1.04 to 1.23), with an interaction P < .001.[5]
Most people buying a compounded prescription on a cash telehealth plan are in the second group, and the difference between the two indications is set out in the article on the two approvals. This is one retrospective database study rather than a randomized result, and its authors say prospective work is needed to establish causality.
Whether to pursue weight loss at all is contested
A 2025 clinical review notes that United States guidelines do not address weight loss in older adults, and that waist circumference may be a more accurate assessment tool than body-mass index in this group. It reports that weight-loss interventions are not recommended in older adults who are merely overweight, because of the lower mortality observed in that band.[6]
The same review lists the risks it considers greatest: loss of muscle mass, decline in bone mineral density, and the development of sarcopenic obesity. It places the case for intervening at a body-mass index above 30 alongside metabolic derangements, cardiovascular disease or functional impairment, after the risks have been weighed against the benefits.[6]
Polypharmacy belongs to a prescriber and a pharmacist
That review also names why medications are the harder part of the calculation after 65: enhanced adverse-effect profiles, interactions, contraindications and cost.[6] None of those four is knowable from a marketing page, and all four are knowable from a medication list.
So the practical reading is about intake rather than about the drug. A service that collects a current medication list, a fall history and a renal function result has gathered what the assessment requires. One that asks for a height, a weight and a card number has not, which is one of the patterns in the telehealth article. Coverage is a separate obstacle at this age, and the Medicare history behind it is in the coverage article.
What none of this decides
Nothing above argues for or against a prescription at any age. The efficacy evidence in older adults is thin but consistent. The safety signal that differs is gastrointestinal and glycemic rather than catastrophic. And the questions that matter most to a geriatric prescriber are the ones carrying the least data.
That combination is a reason to route the decision to someone holding the chart rather than to resolve it from a website. What this site publishes is what the sellers state and what the trials measured, recorded in the seller write-ups and established the way the methodology describes.